[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100290215":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":11,"centralContacts":16,"locations":25,"responsibleParty":70,"collaborators":7,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":7,"maxAge":7,"enrollmentInfo":81,"targetDuration":84,"studyType":85,"phases":7,"briefSummary":86,"conditions":87,"keywords":7,"overallStatus":28,"whyStopped":7,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Technische Universität Dresden","OTHER",null,[9],{"type":6,"name":10,"description":7,"armGroupLabels":7,"otherNames":7},"No study intervention",[12],{"name":13,"affiliation":14,"role":15},"Jochen Schmitt, Prof.Dr.","Center for Evidence-based Healthcare, Technical University Dresden","PRINCIPAL_INVESTIGATOR",[17,21],{"name":13,"role":18,"phone":19,"phoneExt":7,"email":20},"CONTACT","+493514586493","jochen.schmitt@uniklinikum-dresden.de",{"name":22,"role":18,"phone":23,"phoneExt":7,"email":24},"Eva Haufe, Dr.","+493514586491","eva.haufe@uniklinikum-dresden.de",[26,43,57],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Clinics for Dermatology, Allergy and Venerology, Hannover Medical School","RECRUITING","Hanover","Lower Saxony","30625","Germany","DE",{"type":35,"coordinates":36},"Point",[37,38],9.73322,52.37052,{"lat":38,"lon":37},[41],{"name":42,"role":18,"phone":7,"phoneExt":7,"email":7},"Thomas Werfel, Prof.",{"facility":44,"status":28,"city":45,"state":46,"zip":47,"country":32,"countryCode":33,"cosmosGeoPoint":48,"geoPoint":52,"contacts":53},"Department of Dermatology, UniversityAllergyCenter, Medical Faculty Carl Gustav Carus, TU Dresden","Dresden","Saxony","01307",{"type":35,"coordinates":49},[50,51],13.73832,51.05089,{"lat":51,"lon":50},[54,56],{"name":55,"role":18,"phone":7,"phoneExt":7,"email":7},"Susanne Abraham, Dr.",{"name":55,"role":15,"phone":7,"phoneExt":7,"email":7},{"facility":58,"status":28,"city":59,"state":60,"zip":61,"country":32,"countryCode":33,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Head Centre for Inflammatory Skin Diseases, Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel","Kiel","Schleswig-Holstein","24105",{"type":35,"coordinates":63},[64,65],10.13489,54.32133,{"lat":65,"lon":64},[68],{"name":69,"role":18,"phone":7,"phoneExt":7,"email":7},"Stephan Weidinger, Prof.",{"type":71,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100290215","treatgermany-german-national-clinical-registry-for-patients-with-moderate-to-severe-atopic-dermatitis-100290215",false,"NCT03057860","TREATgermany: German National Clinical Registry for Patients With Moderate-to-severe Atopic Dermatitis","TREATgermany: German National Clinical Registry: Treatment and Medical Care of Patients With Moderate-to-severe Atopic Dermatitis","TREATgermany","Inclusion Criteria:\n\n* AD according to the United Kingdom (UK) working party diagnostic criteria\n* Moderate to severe AD\n* Objective SCORAD \\> 20 or Currently anti-inflammatory systemic treatment for AD or Previous anti-inflammatory systemic treatment for AD within past 24 months\n\nExclusion Criteria:\n\n\\-","ALL",{"count":82,"type":83},2800,"ESTIMATED","5 Years","OBSERVATIONAL","About 60% of all patients with AD are adults. However, the prevalence and incidence is significantly higher in childhood and adolescence.\n\nSome children, adolescents and adults with moderate-to-severe AD cannot be sufficiently controlled with topical treatments alone and require intermittent or continuous treatment with systemic immunomodulating agents or UV-therapy.\n\nSystematic reviews indicate that although several different interventions for moderate-to-severe AD have been studied in clinical trials, strong recommendations are only possible for Dupilumab in adults and the short-term use of cyclosporin A (CSA).\n\nPharmaceutical treatment of patients suffering from AE is diverse and frequently not in line with the current guidelines (for example S2-guideline in Germany).\n\nLarge head-to-head trials are missing so that long-term effectiveness of systemic interventions for moderate-to-severe AD is speculative.\n\nIn this situation, clinical registries can provide valuable information for evidence-based clinical decision making.\n\nExtension of TREATgermany to children and adolescents is necessary as\n\n* moderate-to-severe AD is frequent in this age group, but the effectiveness of existing topical and systemic agents in the routine care setting on clinical severity, patient-reported outcomes, and the course of AD and associated atopic and non-atopic comorbidities over time is still poorly understood\n* it is unclear how many children and adolescents cannot be effectively controlled with the avoidance of trigger factors, patient education, and topical anti-inflammatory treatment alone\n* innovative agents will become available for these age groups within the next years and reference data will be necessary to evaluate their effectiveness and indication criteria\n* adequate evidence regarding patient needs in children and adolescents with moderate-to-severe AD is urgently needed to provide value-based healthcare for this vulnerable patient group\n* Best-practice models of transition from adolescent to adult care of patients with moderate-to-severe AD do not exist yet, but constitute a prerequisite for the establishment of efficient patient care",[88],"Moderate-to-severe Atopic Dermatitis","2022-05-03",{"date":91,"type":92},"2022-05-09","ACTUAL",{"date":94,"type":92},"2016-02-01",{"date":96,"type":83},"2026-12-31",{"name":5,"class":6},3]